Nov 27 (Reuters) - Xenon Pharmaceuticals said on Monday its experimental drug to treat severe major depressive disorder had failed to meet the main goal in a mid-stage study. (Reporting by Mariam Sunny in Bengaluru; Editing by Pooja Desai)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
38.64 USD | +1.78% | +1.07% | -16.26% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.26% | 2.86B | |
+17.48% | 124B | |
+15.52% | 109B | |
-6.98% | 23.84B | |
+2.18% | 22.42B | |
-14.29% | 17.5B | |
-9.94% | 16.61B | |
-37.63% | 16.43B | |
+2.11% | 13.4B | |
+26.62% | 11.47B |
- Stock Market
- Equities
- XENE Stock
- News Xenon Pharmaceuticals Inc.
- Xenon Pharmaceuticals' depression drug fails to meet main goal in study